Fresenius stock: DZ Bank keeps Buy rating
Published on 11/18/2026 at 17:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst support and late trading
- DZ Bank retained its Buy rating for Fresenius in a report released on November 17.
- The group continues to convert its Fresenius Medical Care stake sale into capital for growth investments.
- Fresenius stock traded below the November 18 Xetra close in late-session trading.
Fresenius stock: DZ Bank keeps Buy rating
DZ Bank retained its Buy rating for Fresenius in a report released on Tuesday, November 17, according to Longbridge. The analyst action gives investors a fresh view on the healthcare group's shares after recent portfolio and earnings developments.
DZ Bank keeps its stance
The report did not change DZ Bank's Buy recommendation. Longbridge also cited a separate Barclays report that maintained a Buy rating with a 65.00 euro price target, although that target came from Barclays rather than DZ Bank.
The analyst signal follows Fresenius' completed sale of 13.4 million Fresenius Medical Care shares. The transaction generated gross proceeds of 524 million euros and reduced Fresenius' holding in the dialysis business to about 20 percent. Management has indicated that the proceeds create room for investments in growth areas.
Late-session share performance
Fresenius stock traded at 53.41 euros on Lang & Schwarz at 17:40 CET on Wednesday, November 18, 2026, 0.54 percent below the Xetra close of Wednesday, November 18, at 53.70 euros.
The late-session quote puts the shares below the Xetra close while the analyst stance remains positive. The rating and the share price represent separate signals and do not establish a direct market reaction to the report.
Fresenius stock at a glance
- Company: Fresenius SE & Co. KGaA
- ISIN: DE000FRE5EN2
- Lang & Schwarz: 53.41 euros at 17:40 CET on November 18, 2026
- Xetra close: 53.70 euros on November 18, 2026
- Day change against Xetra: -0.54 percent
Germany's wider equity market is covered in Current market reports.
More updates are available in More news and analyses on Fresenius stock.
